Menu Search
Equities

Lantheus Holdings Inc

0L8:DUS

Lantheus Holdings Inc

Actions
  • Price (EUR)86.30
  • Today's Change0.64 / 0.75%
  • Shares traded30.00
  • 1 Year change+38.84%
  • Beta--
Data delayed at least 15 minutes, as of Nov 26 2024 08:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its pipeline also includes breast and other cancers. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, Ga-DOTA-RM2, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol.

  • Revenue in USD (TTM)1.50bn
  • Net income in USD427.61m
  • Incorporated2007
  • Employees834.00
  • Location
    Lantheus Holdings Inc331 Treble Cove RdNORTH BILLERICA 01862United StatesUSA
  • Phone+1 (978) 671-8001
  • Fax+1 (302) 636-5454
  • Websitehttps://www.lantheus.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		LNTH:NMQ since
announced		Transaction
value
Meilleur Technologies IncDeal completed15 Jul 202415 Jul 2024Deal completed-26.30%--
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.